|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
| We’re going down soon, to move to a new Data Center today. We’ll be up ASAP. Sorry. |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/30/21 Cell MedX Corp. 10-K 5/31/21 83:3.7M Empire Stock Transf… Inc |
Document/Exhibit Description Pages Size
1: 10-K Cell Medx Corp. - Form 10-K SEC Filing HTML 680K
2: EX-10.36 Loan Agreement and Note Payable Dated March 29, HTML 27K
2021
3: EX-10.37 Loan Agreement and Note Payable Dated April 15, HTML 27K
2021
4: EX-10.38 Loan Agreement and Note Payable Dated May 18, 2021 HTML 27K
5: EX-10.41 Loan Agreement and Note Payable Dated June 22, HTML 27K
2021
6: EX-21.1 List of Significant Subsidiaries HTML 23K
7: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
8: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
10: EX-32.2 Certification -- §906 - SOA'02 HTML 24K
17: R1 Document and Entity Information HTML 78K
18: R2 Consolidated Balance Sheets HTML 107K
19: R3 Consolidated Statements of Operations HTML 100K
20: R4 Consolidated Statement of Stockholders' Deficit HTML 84K
21: R5 Consolidated Statements of Cash Flows HTML 104K
22: R6 Organization and Nature of Operations HTML 29K
23: R7 Summary of Significant Accounting Policies HTML 41K
24: R8 Related Party Transactions Disclosure HTML 43K
25: R9 Inventory Disclosure HTML 26K
26: R10 Other Current Assets Disclosure HTML 26K
27: R11 Equipment Disclosure HTML 32K
28: R12 Revenue Disclosure HTML 32K
29: R13 Distribution Rights Disclosure HTML 34K
30: R14 Notes and Advances Payable Disclosure HTML 54K
31: R15 Share Capital Disclosure HTML 60K
32: R16 Income Taxes Disclosure HTML 44K
33: R17 Subsequent Events Disclosure HTML 27K
34: R18 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis HTML 26K
of Presentation (Policies)
35: R19 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 27K
Principles of Consolidation, Policy (Policies)
36: R20 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 28K
Accounting Estimates, Policy (Policies)
37: R21 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 27K
Foreign Currency Translations and Transactions,
Policy (Policies)
38: R22 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 27K
Revenue Recognition, Policy (Policies)
39: R23 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 28K
Inventory Valuation, Policy (Policies)
40: R24 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 27K
Research and Development Costs, Policy (Policies)
41: R25 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Income HTML 29K
Taxes, Policy (Policies)
42: R26 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Loss HTML 27K
Per Share, Policy (Policies)
43: R27 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 27K
Long-lived Assets, Policy (Policies)
44: R28 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 27K
Equipment, Policy (Policies)
45: R29 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair HTML 28K
Value Measurements, Policy (Policies)
46: R30 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock HTML 27K
Options and Other Stock-based Compensation, Policy
(Policies)
47: R31 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent HTML 26K
Accounting Pronouncements (Policies)
48: R32 Related Party Transactions Disclosure: Schedule of HTML 33K
Amounts Due to Related Parties (Tables)
49: R33 Related Party Transactions Disclosure: Schedule of HTML 32K
Transactions with Related Parties (Tables)
50: R34 Equipment Disclosure: Change in book value of the HTML 31K
equipment (Tables)
51: R35 Revenue Disclosure: Schedule of Revenue and HTML 32K
Associated Costs (Tables)
52: R36 Distribution Rights Disclosure: Black-Scholes HTML 28K
Option pricing model (Tables)
53: R37 Distribution Rights Disclosure: Schedule of loss HTML 28K
on reacquisition of the distribution rights
(Tables)
54: R38 Notes and Advances Payable Disclosure: Schedule of HTML 42K
Short-term Loans and Advances Outstanding (Tables)
55: R39 Share Capital Disclosure: Schedule of Stock Option HTML 34K
Activity (Tables)
56: R40 Share Capital Disclosure: Schedule of Stock HTML 29K
Options Outstanding (Tables)
57: R41 Share Capital Disclosure: Schedule of Warrant HTML 34K
Activity (Tables)
58: R42 Share Capital Disclosure: Schedule of Warrant HTML 31K
Details (Tables)
59: R43 Income Taxes Disclosure: Schedule of Effective HTML 34K
Income Tax Rate Reconciliation (Tables)
60: R44 Income Taxes Disclosure: Schedule of Deferred Tax HTML 32K
Assets and Liabilities (Tables)
61: R45 Organization and Nature of Operations (Details) HTML 27K
62: R46 Related Party Transactions Disclosure: Schedule of HTML 40K
Amounts Due to Related Parties (Details)
63: R47 Related Party Transactions Disclosure: Schedule of HTML 36K
Transactions with Related Parties (Details)
64: R48 Inventory Disclosure (Details) HTML 31K
65: R49 Other Current Assets Disclosure (Details) HTML 28K
66: R50 Equipment Disclosure: Change in book value of the HTML 34K
equipment (Details)
67: R51 Revenue Disclosure: Schedule of Revenue and HTML 49K
Associated Costs (Details)
68: R52 Distribution Rights Disclosure (Details) HTML 28K
69: R53 Notes and Advances Payable Disclosure: Schedule of HTML 46K
Short-term Loans and Advances Outstanding
(Details)
70: R54 Notes and Advances Payable Disclosure (Details) HTML 72K
71: R55 Share Capital Disclosure (Details) HTML 83K
72: R56 Share Capital Disclosure: Schedule of Stock Option HTML 38K
Activity (Details)
73: R57 Share Capital Disclosure: Schedule of Stock HTML 32K
Options Outstanding (Details)
74: R58 Share Capital Disclosure: Schedule of Warrant HTML 32K
Activity (Details)
75: R59 Share Capital Disclosure: Schedule of Warrant HTML 36K
Details (Details)
76: R60 Income Taxes Disclosure: Schedule of Effective HTML 51K
Income Tax Rate Reconciliation (Details)
77: R61 Income Taxes Disclosure: Schedule of Deferred Tax HTML 34K
Assets and Liabilities (Details)
78: R62 Income Taxes Disclosure (Details) HTML 27K
79: R63 Subsequent Events Disclosure (Details) HTML 40K
81: XML IDEA XML File -- Filing Summary XML 148K
16: XML XBRL Instance -- cmxc-20210531_htm XML 727K
80: EXCEL IDEA Workbook of Financial Reports XLSX 73K
11: EX-101.CAL XBRL Calculations -- cmxc-20210531_cal XML 73K
12: EX-101.DEF XBRL Definitions -- cmxc-20210531_def XML 332K
13: EX-101.LAB XBRL Labels -- cmxc-20210531_lab XML 566K
14: EX-101.PRE XBRL Presentations -- cmxc-20210531_pre XML 519K
15: EX-101.SCH XBRL Schema -- cmxc-20210531 XSD 192K
82: JSON XBRL Instance as JSON Data -- MetaLinks 229± 331K
83: ZIP XBRL Zipped Folder -- 0001393905-21-000393-xbrl Zip 155K
| Loan Agreement and Note Payable dated April 15, 2021 |
LOAN AGREEMENT
Richard N. Jeffs (the “Lender”) of 11750 Fairtide Road, Ladysmith, BC V9G 1K5, advanced USD$15,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 123 W. Nye Ln, Suite 446, Carson City, NV 89706. The Lender advanced the funds on April 15, 2021.
The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from April 15, 2021 (the “Effective Date”). The Borrower is liable for repayment of the Principal Sum, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement.
The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
| LENDER | BORROWER |
| Richard N. Jeffs | Cell MedX Corp. |
|
|
|
| Per: | Per: |
|
|
|
|
|
|
| /s/ Richard N. Jeffs | /s/ Yanika Silina |
| Richard N. Jeffs | Yanika Silina, CFO |
PROMISSORY NOTE
| Principal Amount: USD$15,000 |
FOR VALUE RECEIVED Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of Richard N. Jeffs (the “Lender”) the sum of $15,000 lawful money of the United States of America (the “Principal Sum”) together with the Interest accrued on the Principal Sum calculated from April 15, 2021 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
The Borrower may repay the Principal Sum, and the Interest in whole or in part at any time.
The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.
BORROWER
Cell MedX Corp.
Per:
/s/ Yanika Silina
Yanika Silina, CFO
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/30/21 | None on these Dates | ||
| For Period end: | 5/31/21 | |||
| 4/15/21 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/15/24 Cell MedX Corp. 10-Q 2/29/24 53:2.7M Empire Stock Transf… Inc 1/16/24 Cell MedX Corp. 10-Q 11/30/23 46:2.3M Empire Stock Transf… Inc 10/16/23 Cell MedX Corp. 10-Q 8/31/23 42:1.9M Empire Stock Transf… Inc 9/01/23 Cell MedX Corp. 10-K 5/31/23 73:3.2M Empire Stock Transf… Inc 6/29/23 Cell MedX Corp. 10-Q 2/28/23 53:2.5M Empire Stock Transf… Inc 5/19/23 Cell MedX Corp. 10-Q 11/30/22 53:2.4M Empire Stock Transf… Inc 4/19/23 Cell MedX Corp. 10-Q 8/31/22 51:2.2M Empire Stock Transf… Inc 4/07/23 Cell MedX Corp. 10-K 5/31/22 90:3.6M Empire Stock Transf… Inc 4/11/22 Cell MedX Corp. 10-Q 2/28/22 56:2.5M Empire Stock Transf… Inc 1/12/22 Cell MedX Corp. 10-Q 11/30/21 54:2.4M Empire Stock Transf… Inc 10/14/21 Cell MedX Corp. 424B3 1:365K Empire Stock Transf… Inc 10/14/21 Cell MedX Corp. 10-Q 8/31/21 50:2.2M Empire Stock Transf… Inc 10/12/21 Cell MedX Corp. 424B3 1:705K Empire Stock Transf… Inc |